Senior Vice President and Chief Business Officer · CytomX Therapeutics, Inc. (CTMX)

Rachael Lester

FY2025 is the first fiscal year CompBrief holds for Rachael Lester as a named executive officer of CytomX Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$2,234,874

Salary $77,019Bonus $120,000

2nd of 3 named executive officers at CytomX Therapeutics by FY2025 total.

3 named officers on file for CytomX Therapeutics, FY2025

Rachael Lester’s pay file — $29

  • 1 fiscal year of pay, line by line
  • CTMX’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how CytomX Therapeutics’s whole pay program stands against its peers

  • CytomX Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CTMX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2026 (DEF 14A).

Free

Get Rachael Lester’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Rachael Lester compensation by year

CytomX Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as CytomX Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$77,019
Bonus$120,000
Option awards$1,993,355
Non-equity incentive$44,500
Pension and deferred compensation$0
All other$0
Total$2,234,874

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CytomX Therapeutics, Inc. DEF 14A filed April 30, 2026, accession 0001140361-26-018237, and prior-year filings. Open the filing on EDGAR.

How this page was built: the CytomX Therapeutics, Inc. filed document, accession 0001140361-26-018237. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option650,000—$3.74

Per the Outstanding Equity Awards at Fiscal Year-End table in CytomX Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

CytomX Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Sean McCarthyChief Executive Officer and Chairman of the Board of Directors$4,738,495
Rachael Lester · this pageSenior Vice President and Chief Business Officer$2,234,874
Chris OgdenSenior Vice President, and Chief Financial Officer$1,542,631

The full CytomX Therapeutics compensation record

free company brief

This page is one person within CytomX Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the CytomX Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CytomX Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Rachael Lester's compensation dossier · One-time report. No refunds.